A BILL 
To allow the Secretary of Health and Human Services to 
deny approval of a new drug application for an opioid 
analgesic drug on the basis of such drug not being clini-
cally superior to other commercially available drugs. 
Be it enacted by the Senate and House of Representa-
1
tives of the United States of America in Congress assembled, 
2
SECTION 1. SHORT TITLE. 
3
This Act may be cited as the ‘‘Ensuring the FDA 
4
Fully Examines Clinical Trial Impact and Vitalness before 
5
Endorsement Act’’ or the ‘‘EFFECTIVE Act’’. 
6
00:46 Aug 11, 2022
H8586
2 
•HR 8586 IH
SEC. 2. REQUIREMENT FOR APPROVAL OF NEW OPIOID AN-
1
ALGESICS. 
2
Section 505(c) of the Federal Food, Drug, and Cos-
3
metic Act (21 U.S.C. 355(c)) is amended by adding at 
4
the end the following: 
5
‘‘(6) Notwithstanding any other provision of this sec-
6
tion, the Secretary may deny approval of an application 
7
submitted under subsection (b) for an opioid analgesic 
8
drug if the Secretary determines that such drug does not 
9
provide a significant advantage or clinical superiority, in 
10
terms of greater safety or effectiveness, compared to an 
11
appropriate comparator drug, as determined by the Sec-
12
retary.’’. 
13
Æ 
00:46 Aug 11, 2022
H8586
